|
1
|
Park JY, Park SK, Kim DY, et al: The
impact of tumor morcellation during surgery on the prognosis of
patients with apparently early uterine leiomyosarcoma. Gynecol
Oncol. 122:255–259. 2011.
|
|
2
|
Leitao MM Jr, Zivanovic O, Chi DS, et al:
Surgical cytoreduction in patients with metastatic uterine
leiomyosarcoma at the time of initial diagnosis. Gynecol Oncol.
125:409–413. 2012.
|
|
3
|
Svancárová L, Blay JY, Judson IR, et al:
Gemcitabine in advanced adult soft-tissue sarcomas. A phase II
study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J
Cancer. 38:556–559. 2002.
|
|
4
|
Okuno S, Edmonson J, Mahoney M, et al:
Phase II trial of gemcitabine in advanced sarcomas. Cancer.
94:3225–3229. 2002.
|
|
5
|
Gallup DG, Blessing JA, Andersen W and
Morgan MA; Gynecologic Oncology Group Study. Evaluation of
paclitaxel in previously treated leiomyosarcoma of the uterus: a
gynecologic oncology group study. Gynecol Oncol. 89:48–51.
2003.
|
|
6
|
Garcia-Carbonero R, Supko JG, Manola J, et
al: Phase II and pharmacokinetic study of ecteinascidin 743 in
patients with progressive sarcomas of soft tissues refractory to
chemotherapy. J Clin Oncol. 22:1480–1490. 2004.
|
|
7
|
Smith HO, Blessing JA and Vaccarello L:
Trimetrexate in the treatment of recurrent or advanced
leiomyosarcoma of the uterus: a phase II study of the Gynecologic
Oncology Group. Gynecol Oncol. 84:140–144. 2002.
|
|
8
|
Rose PG, Blessing JA, Soper JT and Barter
JF: Prolonged oral etoposide in recurrent or advanced
leiomyosarcoma of the uterus: a gynecologic oncology group study.
Gynecol Oncol. 70:267–271. 1998.
|
|
9
|
Slayton RE, Blessing JA, Angel C and
Berman M: Phase II trial of etoposide in the management of advanced
and recurrent leiomyosarcoma of the uterus: a Gynecologic Oncology
Group Study. Cancer Treat Rep. 71:1303–1304. 1987.
|
|
10
|
Asbury R, Blessing JA, Buller R, et al:
Amonafide in patients with leiomyosarcoma of the uterus: a phase II
Gynecologic Oncology Group study. Am J Clin Oncol. 21:145–146.
1998.
|
|
11
|
Long HJ III, Blessing JA and Sorosky J:
Phase II trial of dacarbazine, mitomycin, doxorubicin, and
cisplatin with sargramostim in uterine leiomyosarcoma: a
Gynecologic Oncology Group study. Gynecol Oncol. 99:339–342.
2005.
|
|
12
|
Edmonson JH, Blessing JA, Cosin JA, et al:
Phase II study of mitomycin, doxorubicin, and cisplatin in the
treatment of advanced uterine leiomyosarcoma: a Gynecologic
Oncology Group study. Gynecol Oncol. 85:507–510. 2002.
|
|
13
|
Currie J, Blessing JA, Muss HB, Fowler J,
Berman M and Burke TW: Combination chemotherapy with hydroxyurea,
dacarbazine (DTIC), and etoposide in the treatment of uterine
leiomyosarcoma: a Gynecologic Oncology Group study. Gynecol Oncol.
61:27–30. 1999.
|
|
14
|
Sutton G, Blessing JA and Malfetano JH:
Ifosfamide and doxorubicin in the treatment of advanced
leiomyosarcomas of the uterus: a Gynecologic Oncology Group study.
Gynecol Oncol. 62:226–229. 1996.
|
|
15
|
Hensley ML, Maki R, Venkatraman E, Geller
G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R and
Spriggs DR: Gemcitabine and docetaxel in patients with unresectable
leiomyosarcoma: results of a phase II trial. J Clin Oncol.
20:2824–2831. 2002.
|
|
16
|
Hensley ML, Blessing JA, Degeest K,
Abulafia O, Rose PG and Homesley HD: Fixed-dose rate gemcitabine
plus docetaxel as second-line therapy for metastatic uterine
leiomyosarcoma: a Gynecologic Oncology Group phase II study.
Gynecol Oncol. 109:323–328. 2008.
|
|
17
|
Wiedemann GJ, Robins HI, Katschinski DM,
et al: Systemic hyperthermia and ICE chemotherapy for sarcoma
patients: rationale and clinical status. Anticancer Res.
17:2899–2902. 1997.
|
|
18
|
Pereira Arias AM, Wester JP, Blankendaal
M, et al: Multiple organ dysfunction syndrome induced by whole-body
hyperthermia and polychemotherapy in a patient with disseminated
leiomyosarcoma of the uterus. Intensive Care Med. 25:1013–1016.
1999.
|
|
19
|
Westermann AM, Jones EL, Schem BC, et al:
First results of triple-modality treatment combining radiotherapy,
chemotherapy, and hyperthermia for the treatment of patients with
stage IIB, III, and IVA cervical carcinoma. Cancer. 104:763–770.
2005.
|
|
20
|
Mohamed F, Marchettini P, Stuart OA, et
al: Thermal enhancement of new chemotherapeutic agents at moderate
hyperthermia. Ann Surg Oncol. 10:463–468. 2003.
|
|
21
|
Reed NS, Mangioni C, Malmström H, et al:
Phase III randomised study to evaluate the role of adjuvant pelvic
radiotherapy in the treatment of uterine sarcomas stages I and II:
an European Organisation for Research and Treatment of Cancer
Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer.
44:808–818. 2008.
|
